© 2022 MJH Life Sciences and Managed Healthcare Executive. All rights reserved.
© 2022 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
Two experts discuss uterine fibroids and treating the disease as both a provider and payer.
February 21st 2022
Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP, provides a comprehensive background on uterine fibroids, explaining everything from clinical burden to symptoms.
Dr Al-Hendy discusses the impact UF has on a patient’s life and their typical patient journey through the healthcare system.
April 8th 2022
Maria Lopes, MD, discusses the economic burden of UF from a payer’s perspective, explaining direct and indirect costs associated with the condition.
Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP, elaborates on risk factors for the development of UF.
April 18th 2022
Dr Ayman Al-Hendy details the shift from surgical options to medical therapy for patients with UF.
Dr Al-Hendy briefly explains how he determines treatment goals during initial workups for patients with UF.
April 22nd 2022
Dr Al-Hendy highlights the oral GnRH receptor antagonists as first-line therapy for UF.
Dr Lopes discusses the typical payer challenges with managing UF treatment, including pain management.
April 29th 2022
Dr Maria Lopes provides an overview of common disparities seen when treating and maintaining women’s reproductive health and how these can be minimized.
Drs Lopes and Al-Hendy describe the unmet needs they see when treating patients with UF.